How to Buy Freeline Therapeutics Holdings Stock
Freeline Therapeutics Holdings PLC
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases.
Freeline Therapeutics Holdings stock last closed at $2.55, up 2% from the previous day, and has decreased 78.25% in one year. It has underperformed other stocks in the Biotechnology industry by 0.65 percentage points. Freeline Therapeutics Holdings stock is currently +20.85% from its 52-week low of $2.11, and -84.82% from its 52-week high of $16.80.
As of Jun 2, 2023, there are 65.11M FRLN shares outstanding. The market capitalization of FRLN is $11.12M. In the past 24 hours, 24,704 FRLN shares were traded.
How to Buy Freeline Therapeutics Holdings Stock
Wondering how to invest in Freeline Therapeutics Holdings stock? Here's how.
- Figure out where to buy Freeline Therapeutics Holdings stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you figure out where to buy Freeline Therapeutics Holdings stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Select your payment method and add your information.
- Research Freeline Therapeutics Holdings stock: The Freeline Therapeutics Holdings ticker symbol is FRLN. Is Freeline Therapeutics Holdings stock a good investment? Should you buy shares of FRLN? How do FRLN's underlying business fundamentals look? Do top analysts think Freeline Therapeutics Holdings is a good buy? Why has FRLN's stock price moved recently? (Hint: Our stock research website can help you understand if FRLN is a good stock to buy).
- Make your FRLN buy order: Decide if you will purchase FRLN shares at the current market price or use a limit order to buy FRLN shares at a given price.
- Watch your investment in FRLN: Create a watchlist to get live updates on your investment in Freeline Therapeutics Holdings stock.
Step 1: Figure out where to buy Freeline Therapeutics Holdings stock
You will need an online brokerage account in order to access the NASDAQ market and buy FRLN stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Tech to Financial Services, New York to London — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal details so you can buy FRLN stock today.
How to Set Up a New Account on eToro
- Click here to get started.
- Provide your personal info to create a new brokerage account.
- Submit your information by pressing the "Create Account" button.
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the best stock trading app for beginners, you can securely and quickly fund your account:
Watch the walkthrough below to see the process of depositing money into your brokerage account.
Step 4: Research Freeline Therapeutics Holdings stock
Once you have decided on the best place to buy Freeline Therapeutics Holdings stock, it's crucial to evaluate their stock before you invest, so you can comprehend the risk and opportunity.
Freeline Therapeutics Holdings shares at a glance
FRLN Zen Score
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on FRLN's stock page.
How is FRLN stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge FRLN's fair value.
Using relative valuations ratios:
- FRLN could be undervalued based on its P/B ratio of 0.2x, relative to Biotechnology industry P/B ratio of 5.2x
You can access additional valuation analysis on FRLN's stock here.
A quick look at FRLN Financials
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the FRLN balance sheet.
- There are more short-term assets than long-term liabilities on the FRLN balance sheet.
Failed Financial Due Diligence Checks:
- FRLN has cash burn of 76961000. It does not have sufficient cash and short-term investments to cover this.
- FRLN has $55.42M in cash and short term investments. This is not sufficient to cover its annual cash burn of $76.96M.
- FRLN has a relatively high debt to equity ratio of 0.45.
Do analysts think it's a good time to buy Freeline Therapeutics Holdings stock
Out of 2 Wall Street analysts who give ratings on FRLN, the consensus analyst rating on Freeline Therapeutics Holdings is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest FRLN Analyst Recommendations
Dae Gon Ha, a bottom 10% analyst from Stifel Nicolaus reiterates FRLN with a hold rating and raises their FRLN price target from $1.00 to $3.00, on Jun 1, 2023.
Patrick Trucchio, a bottom 1% analyst from HC Wainwright & Co. reiterates FRLN with a buy rating and maintains their FRLN price target from $15.00 to $15.00, on May 31, 2023.
You can dive deeper into what analysts are projecting on the Freeline Therapeutics Holdings stock forecast page.
FRLN Momentum
Are FRLN insiders buying or selling the stock?
In the past 12 months, executives and large shareholders at FRLN have not bought or sold any shares.
Research more about who owns FRLN stock here.
Does FRLN stock generate passive income?
No, Freeline Therapeutics Holdings doesn't provide an income stream by paying out dividends.
What do other traders have to say about FRLN?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your FRLN buy order
There are two main options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular price limit, use a limit order.
Press the Open button and your broker will execute your order.
If you require additional help buying stocks on eToro, click the how to video below:
Step 6: Watch your investment in FRLN
Now that you own some FRLN shares, you'll want to stay up-to-date on your shares.
Put FRLN on a watchlist to see the latest developments about your FRLN stock.
FRLN Feed
How to Buy Stock in Freeline Therapeutics Holdings
To reiterate, here are the 6 steps to buy Freeline Therapeutics Holdings stock:
- Figure out where to buy Freeline Therapeutics Holdings stock
- Open your brokerage account
- Deposit funds into your investment account
- Research Freeline Therapeutics Holdings stock
- Make your FRLN buy order
- Watch your investment in FRLN
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Freeline Therapeutics Holdings, hit the button below to create your watchlist.
Trending Content
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.